Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 5Lymphoid 5Other hematologic neoplasm 2Thoracic 1Gynecologic 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Plasma Cell 1

Interventions

venetoclax 157Cytarabine 117Cyclophosphamide 110Specimen Handling 103Azacitidine 103fludarabine 89Biopsy 78Rituximab 50Methotrexate 45Daunorubicin 45fludarabine phosphate 41Vincristine 38Dexamethasone 37Injections 36Magnetic Resonance Spectroscopy 35Decitabine 35Granulocyte Colony-Stimulating Factor 32blinatumomab 31Mycophenolic Acid 30Idarubicin 30Whole-Body Irradiation 29ibrutinib 27Tacrolimus 27Prednisone 27Etoposide 27Doxorubicin 27Busulfan 27acalabrutinib 24Melphalan 24Filgrastim 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hyaluronoglucosaminidase × Other hematologic neoplasm × 90 days × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡